Clinical Research Solutions

FDA Prepares for GDUFA Commitments with Controlled Correspondence Guidance

With the implementation of GDUFA, FDA defined the rules and specific protocol for submitting controlled correspondence to the Office of Generic Drugs (OGD) in a draft guidance published on August 27,...

Clinical Research Solutions

FDA Aims to Standardize REMS Programs

On September 23, FDA released a report regarding “Standardizing and Evaluating Risk Evaluation and Mitigation Strategies (REMS)”. This fulfills FDA’s PDUFA commitment to issue a report of findings...

Clinical Research Solutions

FDA Updates Informed Consent Guidance

FDA recently updated its informed consent guidance in the form of an Information Sheet. The new document reflects the Agency’s current thinking on the informed consent process utilized in...

Clinical Research Solutions

New 510(k) Guidance Bans 'Split Predicates'

Medical device manufacturers may need to re-think their approach to demonstrating substantial equivalence (SE) in the 510(k) notification process, due to the FDA’s recent finalization of the guidance...

Clinical Research Solutions

Monoclonal Antibody Sameness - Effects on Orphan Drug Development

We note with interest FDA’s recently released Guidance for Industry: Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations (April 2014). The guidance summarizes the...

Clinical Research Solutions

FDA Thinking on Biosimilar Immunogenicity Issues - A Case Study Based on the Enoxaparin ANDA Approval

Following extensive marketing of Lovenox® (enoxaparin sodium), a low-molecular weight heparin, a number of biosimilar versions of enoxaparin and one ANDA-approved formulation (enoxaparin sodium,...

Clinical Research Solutions

What Can Testosterone Gels Teach Us About Abuse-Deterrent Opioids?

For most drugs, the process of developing and obtaining FDA approval of a generic version is simple and well-defined: sponsors must only prove that their product is pharmaceutically equivalent and...

Clinical Research Solutions

Rethinking the OTC Monograph System

When the OTC drug review was undertaken in the 1970s, it was deemed the best solution available at the time for efficiently assessing the safety and efficacy of the countless drug products being sold...

Clinical Research Solutions

FDA Revisits the Topic of INDs for Dietary Supplements

One of the fundamental disconnects in the dietary supplement world is that despite the fact that manufacturers of dietary supplements are not allowed to make claims regarding effects on diseases,...

Clinical Research Solutions

FDA Issues a Reminder on Excipients in Dietary Supplements

In the new guidance on substances that can be added to foods, including beverages and dietary supplements, the FDA reminds manufacturers that the excipients added to oral dosage forms of these...

Prev 3 4 5 6 7